Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
BioSpace
In addition to delivering two approved medicines to Biogen's portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma's own kidney disease asset, currently in
pharminent
March 31, 2026 (Last updated: March 31, 2026)
BioSpace
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in
